Women with de novo metastatic breast cancer that is confined to a single distant organ may live longer when they undergo resection of the primary tumor, a large cohort study suggested. The study, of ...

"While patients at risk of frailty and limited life expectancy are common in our population, these measures do not appear to significantly influence patient and clinician treatment decision making." — ...

Daraxonrasib received FDA breakthrough therapy designation for metastatic PDAC with KRAS G12 mutations, expediting its development. The designation is based on promising phase 1 trial results, with ...

Medically reviewed by Doru Paul, MD Key Takeaways Survival rates for stage 3 lung cancer can vary between 13% to 36% depending on the subtype.Stage 3a lung cancer is often treated with surgery and ...